Evercare, Leading Healthcare Platform, Appoints New CEO

Industry expert Massimiliano Colella will drive growth and access to affordable and quality care across the Evercare platform

DUBAI, United Arab Emirates–(BUSINESS WIRE)–Evercare, a healthcare delivery platform that operates hospitals, clinics and diagnostic facilities across Africa and South Asia, today announced the appointment of Massimiliano (Max) Colella as Chief Executive Officer, effective January 1, 2020. Mr. Colella will continue to strengthen Evercare’s leadership position by driving growth and operational excellence at existing facilities, leveraging technology to improve the delivery and cost of healthcare, bringing projects in development to market, and searching for new and complementary investments.

“Throughout my nearly three decades of working in the healthcare industry in Africa, Asia and the Middle East, I have seen first-hand what is needed to build strong healthcare systems in these regions. I look forward to leveraging that experience to help strengthen Evercare’s leadership position, with the ultimate goal of reaching more patients with the highest quality care,” said Mr. Colella.

Evercare is wholly owned by The Evercare Health Fund, a $1B emerging markets healthcare fund managed by The Rise Fund, the impact investment platform of global alternative asset manager TPG. The Evercare Health Fund is comprised of the world’s leading development finance institutions and other impact investors.

Matthew Hobart, Co-Managing Partner of TPG Growth and head of healthcare investing for The Rise Fund, said, “There is an urgent need to expand the delivery of affordable high-quality healthcare across the emerging markets. We are excited to have Max joining the Evercare leadership team and believe his extensive expertise in scaling global healthcare businesses will meaningfully advance Evercare’s mission.”

Mr. Colella has over 27 years of experience in the medical device industry. He joins Evercare from Smith & Nephew, a leading medical technology company, where he was President of Europe, Middle East, and Africa, and previously served as Senior Vice President of Asia Pacific and Emerging Markets.

Prior to that, Mr. Colella spent 21 years at Johnson & Johnson in a number of national and international roles in Europe and Emerging Markets within the Ethicon and DePuy Synthes franchises.

About Evercare

Evercare is an integrated healthcare delivery platform operating in growth markets across Africa and South Asia, including India, Pakistan, Kenya and Nigeria. Evercare helps communities thrive by improving hospital operations and leveraging technology and integration to increase the quality of care. Evercare is building a foundation of continuous quality improvement and standardized care to improve clinical outcomes and patient safety. Evercare’s portfolio includes 27 hospitals, 18 clinics, 45 diagnostics centers and one brownfield asset. Evercare is wholly owned by the Evercare Health Fund, a $1B emerging markets healthcare fund managed by The Rise Fund, the impact investment platform of global alternative asset manager TPG. The Evercare Health Fund is comprised of the world’s leading development finance institutions and other impact investors around the world.

Contacts

Frank Thomas (The Rise Fund)

Fthomas@therisefund.com
212 601 4711

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

55 mins ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

55 mins ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

55 mins ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

55 mins ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

55 mins ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

55 mins ago